India, June 20 -- Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid or BP.
Dupixent is now the only targeted medicine to treat patients with BP in the U.S.
BP, which primarily affects elderly patients, is a chronic, debilitating and relapsing rare skin disease, characterized by intense itch, painful blisters and lesions, as well as reddening of the skin. It is affecting around 27,000 adults in the country whose disease is uncontrolled by systemic corticosteroids.
Dupixent is an injection administered under the skin (subcutaneous injection) at different ...